Patient-derived Organoid Model and Circulating Tumor Cells for Treatment Response of Lung Cancer

Patient-derived Organoid Model and Circulating Tumor Cells for Treatment Response of Lung Cancer (CTMS 18-0056)

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03655015

Enrollment

150

Registered

2018-08-31

Start date

2018-10-16

Completion date

2029-12-01

Last updated

2026-04-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Neoplasm

Brief summary

Create a living biobank of PDOs from Stage I-III lung cancer patients.

Detailed description

Creation a living biobank of PDOs from Stage I-IV lung cancer patients (n=50). We selected enrollment of at least 50 patients so that they can be risk stratified based on lung tumor type, staging and we plan to store these PDOs in biobank for future experiments. For each patient, tumor specimens will be collected at time of their surgery. No specific therapeutic intervention or treatment is provided as part of this study. 1. Establishment and culture of PDOs from lung cancer tumor specimens. PDOs will be biobanked for future experiments. 2. Lung organoids and CTCs will also be cultured and used to study baseline tumor characteristics using histology, immunohistochemistry, atomic force measurements; as well as, oncogenic signaling pathways and proteomic profile of lung organoids and CTCs derived from lung cancer patients (n\>50). 3. Patient demographic information and data to be collected using a patient survey data sheet with treatment and survival history collected at pre-defined time period per the protocol schedule.

Interventions

PROCEDURELung Tumor Resection

Lung Tumor Resection

Study design

Observational model

OTHER

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Read, consented to and signed the IRB-approved informed consent form prior to any study related procedure. * Diagnosis of lung cancer or lung mass or lymphadenopathy that will either systemic treatment or tumor resection as part of standard of care * Any clinical stage of lung cancer * Adult patients ≥18 years of age * Able and willing to complete a questionnaire on their environmental/occupational exposures and smoking/alcohol history

Exclusion criteria

* At the discretion of the treating physician, patient will not be able to fulfill the requirements of the study.

Design outcomes

Primary

Measure	Time frame	Description
To establish and characterize a biobank of patient-derived organoids (PDOs), and investigate the potential of PDOs to recapitulate ex vivo responses to chemotherapeutic and targeted agents observed in the clinic.	10 years	Establishment of a living biobank of PDOs and the potential of PDOs to repeat their process outside a living organism

Secondary

Measure	Time frame	Description
Correlation of PDO and Circulating tumor cells (CTCs)	10 years	To establish a connection between PDOs and CTCs, and their relationship to cancer

Countries

United States

Contacts

CONTACTJosephine Taverna, MD

tavernaj@uthscsa.edu210-450-8234

PRINCIPAL_INVESTIGATORJosephine Taverna, MD

UT Health San Antonio M.D. Anderson Cancer Center

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 21, 2026